Theseu Form News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Theseu form. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Theseu Form Today - Breaking & Trending Today

Theseus Pharmaceuticals Announces Business Highlights and Reports Second Quarter 2023 Financial Results

IND submission for THE-349 in EGFR-mutant NSCLC expected in Q4 2023 Development candidate nomination for BCR-ABL program in CML and Ph+ ALL expected in H1 2024. ....

United Kingdom , United States , Tim Clackson , Josh Rappaport , Prnewswire Theseus Pharmaceuticals Inc , Theseus Pharmaceuticals Inc , Exchange Commission , Drug Administration , Theseus Pharmaceuticals , Chief Executive Officer , Upcoming Expected Milestones , Investigational New Drug Application , Quarter Financial Results , Theseu Form , Quarterly Reports , Consolidated Statements , Health Care Amp Hospitals , Medical Pharmaceuticals ,

Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of THE-630 in Patients with GIST

Decision follows two dose-limiting toxicities related to hand-foot skin reaction observed in Cohort 7 (27 mg) Company prioritizing THE-349, a. ....

United States , United Kingdom , Tim Clackson , Josh Rappaport , Drug Administration , Prnewswire Theseus Pharmaceuticals Inc , Theseus Pharmaceuticals Inc , Exchange Commission , Theseus Pharmaceuticals , Chief Executive Officer , Investigational New Drug Application , Theseu Form , Quarterly Reports ,

Theseus Pharmaceuticals (THRX) to Terminate Development of THE-630 in Patients with GIST

Theseus Pharmaceuticals (THRX) to Terminate Development of THE-630 in Patients with GIST
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , Josh Rappaport , Tim Clackson , Exchange Commission , Theseus Pharmaceuticals Inc , Theseus Pharmaceuticals , Prnewswire Theseus Pharmaceuticals Inc , Drug Administration , Chief Executive Officer , Investigational New Drug Application , Theseu Form , Quarterly Reports ,

Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST

THE-630 demonstrates encouraging safety profile through Cohort 6 , supportive of continued dose escalation
Dose-dependent reductions observed in ctDNA KIT-mutant allele fractions for both. | May 25, 2023 ....

United Kingdom , United States , Josh Rappaport , Christen Baglaneas , Tim Clackson , Suzanne George , David Kerstein , Clinical Development Plan , Corporate Communications Investor Relations , Dana Farber Cancer Institute , Theseus Pharmaceuticals , Exchange Commission , Theseus Pharmaceuticals Inc , Sarcoma Center , Predictive Resistance Assay , Chief Executive Officer , Associate Division Chief , Chief Medical Officer , Trial Background , Clinical Development , Theseu Form , Quarterly Reports , Corporate Communications , Nc Stock Exchange , Press Release , Or Thrx Us88369m1018 ,

Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST

THE-630 demonstrates encouraging safety profile through Cohort 6 (18 mg), supportive of continued dose escalation Dose-dependent reductions observed. ....

United Kingdom , United States , Christen Baglaneas , Tim Clackson , Suzanne George , David Kerstein , Josh Rappaport , Theseus Pharmaceuticals Inc , Sarcoma Center , Exchange Commission , Dana Farber Cancer Institute , Theseus Pharmaceuticals , Clinical Development Plan , Corporate Communications Investor Relations , Predictive Resistance Assay , Chief Executive Officer , Associate Division Chief , Chief Medical Officer , Trial Background , Clinical Development , Theseu Form , Quarterly Reports , Corporate Communications ,